LAVA Therapeutics N.V. (LVTX) annual income statement — 6-year revenue, gross profit & net income history
| Sales/Revenue | 4.99M | 11.98M | 6.77M | 19.39M | 5.35M | 3.75M | 0 |
| Revenue Growth % | -32.06% | 77.01% | -65.09% | 262.45% | 42.78% | - | - |
| Cost of Goods Sold | 24.55M | 0 | 3.48M | 0 | 0 | 15.7M | 8.35M |
| COGS % of Revenue | - | - | 51.44% | - | - | 419.03% | - |
| Gross Profit | -19.56M | 11.98M | 3.29M | 19.39M | 5.35M | -11.95M | -8.35M |
| Gross Margin % | -391.98% | 100% | 48.56% | 100% | 100% | -319.03% | - |
| Gross Profit Growth % | - | 264.53% | -83.05% | 262.45% | 144.75% | -43.21% | - |
| Operating Expenses | 9.97M | 41.67M | 46.68M | 54.23M | 48.96M | 2.72M | 1.24M |
| OpEx % of Revenue | - | 347.81% | 689.63% | 279.66% | 915.2% | 72.56% | - |
| Selling, General & Admin | 15.78M | 13.22M | 14.12M | 14.12M | 12.02M | 2.72M | 1.24M |
| SG&A % of Revenue | - | 110.37% | 208.63% | 72.84% | 224.64% | 72.56% | - |
| Research & Development | 18.74M | 28.45M | 32.56M | 40.1M | 36.95M | 15.7M | 8.35M |
| R&D % of Revenue | - | 237.44% | 481% | 206.82% | 690.56% | 419.03% | - |
| Other Operating Expenses | -1000K | 0 | 0 | 0 | 0 | -15.7M | -8.35M |
| Operating Income | -29.53M | -29.69M | -43.39M | -34.84M | -43.61M | -14.67M | -9.58M |
| Operating Margin % | -591.7% | -247.81% | -641.07% | -179.66% | -815.2% | -391.59% | - |
| Operating Income Growth % | - | 31.57% | -24.56% | 20.12% | -197.23% | -53.11% | - |
| EBITDA | -29.32M | -29.23M | -42.78M | -34.06M | -43.05M | -14.46M | -9.48M |
| EBITDA Margin % | -587.6% | -243.92% | -632.03% | -175.63% | -804.77% | -385.91% | - |
| EBITDA Growth % | -8.13% | 31.69% | -25.62% | 20.9% | -197.75% | -52.47% | - |
| D&A (Non-Cash Add-back) | 205K | 467K | 612K | 781K | 558K | 213K | 99K |
| EBIT | -22.07M | -23.97M | -41.14M | -31.58M | -41.57M | -14.67M | -9.58M |
| Net Interest Income | 2.54M | 3.24M | 3.2M | 257K | -625K | -342K | -87.3K |
| Interest Income | 3.19M | 3.76M | 3.67M | 339K | 0 | 0 | 0 |
| Interest Expense | 644K | 515K | 470K | 82K | 625K | 342K | 87.3K |
| Other Income/Expense | 6.93M | 5.21M | 1.78M | 3.18M | 1.42M | -1.21M | -104K |
| Pretax Income | -22.59M | -24.48M | -41.61M | -31.66M | -42.2M | -15.88M | -9.69M |
| Pretax Margin % | -452.77% | -204.34% | -614.77% | -163.26% | -788.75% | -423.91% | - |
| Income Tax | 683K | 630K | 257K | 249K | 157K | 43K | 0 |
| Effective Tax Rate % | -3.02% | -2.57% | -0.62% | -0.79% | -0.37% | -0.27% | 0% |
| Net Income | -23.28M | -25.11M | -41.87M | -31.91M | -42.35M | -15.93M | -9.69M |
| Net Margin % | -466.45% | -209.6% | -618.57% | -164.55% | -791.68% | -425.06% | - |
| Net Income Growth % | 15.98% | 40.02% | -31.23% | 24.67% | -165.93% | -64.42% | - |
| Net Income (Continuing) | -23.28M | -25.11M | -41.87M | -31.91M | -42.35M | -15.93M | -9.69M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.87 | -0.94 | -1.57 | -1.23 | -2.14 | -39.90 | -21.65 |
| EPS Growth % | 16.55% | 40.13% | -27.64% | 42.52% | 94.64% | -84.3% | - |
| EPS (Basic) | - | -0.94 | -1.57 | -1.23 | -2.14 | -39.90 | -21.65 |
| Diluted Shares Outstanding | 26.9M | 26.83M | 26.73M | 25.92M | 19.76M | 25.35M | 18.41M |
| Basic Shares Outstanding | 26.9M | 26.83M | 26.73M | 25.92M | 19.76M | 25.35M | 18.41M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying LVTX stock.
For fiscal year 2024, LAVA Therapeutics N.V. (LVTX) reported total revenue of $12.0M.
LAVA Therapeutics N.V. (LVTX) reported a net loss of $25.1M for the fiscal year ending 2024.
LAVA Therapeutics N.V. (LVTX) reported an operating income of $-29.7M, resulting in an operating profit margin of -247.8%. This margin reflects the operational efficiency of the business before interest and taxes.
LAVA Therapeutics N.V. (LVTX) generated $12.0M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.